JP2013534227A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534227A5
JP2013534227A5 JP2013524362A JP2013524362A JP2013534227A5 JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5 JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013524362 A JP2013524362 A JP 2013524362A JP 2013534227 A5 JP2013534227 A5 JP 2013534227A5
Authority
JP
Japan
Prior art keywords
nasal
nose
powder
ingested
sucking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524362A
Other languages
English (en)
Other versions
JP2013534227A (ja
JP6049617B2 (ja
Filing date
Publication date
Priority claimed from DE102010034699A external-priority patent/DE102010034699A1/de
Application filed filed Critical
Publication of JP2013534227A publication Critical patent/JP2013534227A/ja
Publication of JP2013534227A5 publication Critical patent/JP2013534227A5/ja
Application granted granted Critical
Publication of JP6049617B2 publication Critical patent/JP6049617B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

担体物質が固体である、経鼻投与に適合された医薬処方物には、例えば２０〜５００ミクロンの範囲の粒径を有し、鼻から吸い込んで摂取される方法で、すなわち鼻の近傍に保持され、粉末を含有する容器から鼻腔を経由した急速な吸入により投与される粗粉末を含む。担体物質として液体を伴う鼻腔用スプレーまたは点鼻剤に好適な処方物には、水または油中の活性成分溶液が包含される。
JP2013524362A 2010-08-18 2011-07-19 Ｆａｋ阻害剤としてのピリミジン誘導体 Expired - Fee Related JP6049617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010034699.3 2010-08-18
DE102010034699A DE102010034699A1 (de) 2010-08-18 2010-08-18 Pyrimidinderivate
PCT/EP2011/003597 WO2012022408A1 (de) 2010-08-18 2011-07-19 Pyrimidinderivate als fak inhibitoren

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016153334A Division JP6441861B2 (ja) 2010-08-18 2016-08-04 Ｆａｋ阻害剤としてのピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2013534227A JP2013534227A (ja) 2013-09-02
JP2013534227A5 true JP2013534227A5 (ja) 2016-01-07
JP6049617B2 JP6049617B2 (ja) 2016-12-21

Family

ID=44504442

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013524362A Expired - Fee Related JP6049617B2 (ja) 2010-08-18 2011-07-19 Ｆａｋ阻害剤としてのピリミジン誘導体
JP2016153334A Expired - Fee Related JP6441861B2 (ja) 2010-08-18 2016-08-04 Ｆａｋ阻害剤としてのピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016153334A Expired - Fee Related JP6441861B2 (ja) 2010-08-18 2016-08-04 Ｆａｋ阻害剤としてのピリミジン誘導体

Country Status (17)

Country Link
US (1) US8906916B2 (ja)
EP (1) EP2606034B1 (ja)
JP (2) JP6049617B2 (ja)
CN (1) CN103052627B (ja)
AR (1) AR082722A1 (ja)
AU (1) AU2011291110B2 (ja)
CA (1) CA2808540C (ja)
DE (1) DE102010034699A1 (ja)
DK (1) DK2606034T3 (ja)
ES (1) ES2572740T3 (ja)
HR (1) HRP20160562T1 (ja)
HU (1) HUE027846T2 (ja)
IL (1) IL224751A (ja)
PL (1) PL2606034T3 (ja)
RS (1) RS54882B1 (ja)
SI (1) SI2606034T1 (ja)
WO (1) WO2012022408A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010034699A1 (de) * 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
CN103534241B (zh) * 2011-02-17 2015-11-25 癌症疗法Crc私人有限公司 Fak抑制剂
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
JP2015524826A (ja) * 2012-08-17 2015-08-27 キャンサー・セラピューティクス・シーアールシー・ピーティーワイ・リミテッド Ｖｅｇｆｒ３阻害剤
CA2882270A1 (en) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
JPWO2014174745A1 (ja) * 2013-04-26 2017-02-23 国立大学法人京都大学 Ｅｇ５阻害剤
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
WO2015123722A1 (en) * 2014-02-19 2015-08-27 Bionomics Limited Inhibitors
EP4070795A1 (en) 2014-08-25 2022-10-12 Salk Institute for Biological Studies Novel ulk1 inhibitors and methods using same
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT880508E (pt) 1996-02-13 2003-07-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
DE50212771D1 (de) * 2001-10-17 2008-10-23 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
EP1495016A2 (en) * 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GEP20084357B (en) 2002-12-20 2008-04-29 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
KR20080004585A (ko) 2005-04-08 2008-01-09 바이엘 파마슈티칼스 코포레이션 피리미딘 유도체 및 암의 치료에서의 이의 용도
DK2134689T3 (da) 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
EP2249650A4 (en) 2008-02-19 2012-01-11 Glaxosmithkline Llc ANILINOPYRIDINE AS A FAK HEMMER
EP3549934A1 (en) * 2008-06-27 2019-10-09 Celgene CAR LLC Heteroaryl compounds and uses thereof
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
TW201024281A (en) * 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
DE102010034699A1 (de) * 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
CN103534241B (zh) * 2011-02-17 2015-11-25 癌症疗法Crc私人有限公司 Fak抑制剂
CA2827172C (en) * 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors

Similar Documents

Publication Publication Date Title
JP2014509313A5 (ja)
JP2013534227A5 (ja)
JP2014526447A5 (ja)
JP2013544781A5 (ja)
JP2013541565A5 (ja)
JP2015505541A5 (ja)
RU2015121091A (ru) Порошки для ингаляции с ультранизкой плотностью
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
MX371521B (es) Sistema de inhalacion de polvo seco.
BR122021002471B8 (pt) Dispositivo de distribuição de droga nasal
CL2013000153A1 (es) Metodo para entregar una solucion de un medicamento a un ojo de un sujeto que lo necesita, comprende, el proveer gotitas que contienen dicho medicamento, en donde dichas gotitas tienen un tamaño promedio de gotita por lo menos de aproximadamente 15 micrones y una velocidad de eyeccion inicial promedio entre 1 m/s y 5 m/s, y entregar dicho medicamento a dicho ojo, donde entre aproximadamente 80% y 100% de la masa de dichas gotitas es depositado en el ojo.
JP2017502064A5 (ja)
ATE527976T1 (de) Vorrichtung zur lagerung, unmittelbaren zubereitung und verabreichung eines wirkstoffes
MX354163B (es) Sistemas y métodos de suministro de fármaco en polvo seco.
WO2010029441A3 (en) Nasal delivery
WO2012024595A3 (en) Circumferential aerosol device for delivering drugs to olfactory epithelium and brain
RS53243B (en) INSTRUMENT, MEDIUM DOSIER - FOR SOLID DOSAGE OF MEDICINES, AS A PRACTICAL EXAMPLE OF USE OF INJECTS AND MEDIUM DOSIER
JP2014528470A5 (ja)
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
JP2020527377A5 (ja)
WO2013038268A8 (en) Tamper resistant immediate release formulations
JP2014530231A5 (ja)
JP2016539921A5 (ja)
EA201590734A8 (ru) Вдыхаемые лекарственные средства
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой